Mankind Pharma IPO price band, GMP, Allotment, Listing date and Price

Mankind Pharma IPO details (25 – 27 April), (Price: 1026-1080)

Mankind Pharma IPO price band, GMP, Allotment, Listing date and Price
Mankind Pharma IPO price band, GMP, Allotment, Listing date and Price

Listing date and Listing Price of Mankind Pharma IPO:

  1. Mankind Pharma IPO listed on BSE and NSE exchanges on – Click Here
  2. Listing Price of Mankind Pharma IPO on NSE – Click Here
  3. Listing Price of Mankind Pharma IPO on BSE – Click Here

Grey Market premium (GMP) price of Mankind Pharma IPO :

Grey Market premium (GMP) price of Mankind Pharma IPO is Rs __. Grey Market premium (GMP) of Mankind Pharma IPO means, unofficially if someone buys or sells his application at a fixed rate irrespective of listing price. Check latest GMP of all IPOs.

Mankind Pharma IPO Allotment link status on Kfintech:

Check the allotment status of Mankind Pharma IPO on these three links given by Kfintech.

  1. Mankind Pharma IPO Allotment Link 1 – https://kosmic.kfintech.com/ipostatus/
  2. Mankind Pharma IPO Allotment Link 2 – https://kcas.kfintech.com/ipostatus/
  3. Mankind Pharma IPO Allotment Link 3 -https://evault.kfintech.com/ipostatus/

Mankind Pharma IPO Allotment link status on Kfintech can be checked by Application No or DPID/Client ID or PAN and enter ‘Captcha’.

Mankind Pharma IPO Allotment link status on Kprism app:

KPRISM, an app by KFin Technologies Pvt Ltd (Registrar of this IPO) can be downloaded from Play Store on mobile or Tab.

  1. Download KPRISM app by KFin Tech.
  2. Select IPO Status (No need to do login or register to check IPO allotment)
  3. Select Mankind Pharma IPO from the list.
  4. Enter Application Number or DPID Client ID or PAN, then Submit.
  5. The allotment status of Mankind Pharma IPO, with no. of shares allotted will come.

Mankind Pharma IPO subscription status details:

 

QIB (Qualified Institl. Bidders)NII (bids above ₹10L)NII (bids below ₹10L)RII (Retail)Total No. of times applied
Day 1
Day2
Day 3     

Mankind Pharma IPO subscription status live

Mankind Pharma IPO highlights:

Mankind Pharma IPO bid Opens on 25 April 2023
Mankind Pharma IPO bid Closes on27 April 2023
Post issue Modification Period28 April 2023 (10 to 11 am)
Cut-off time for UPI Mandate Confirmation28 April 2023 (up to 12:00 pm)
Issue type100% Book Building
Mankind Pharma IPO issue size₹ 4326.36 Cr
Face value of each equity shareRs. 1
Mankind Pharma IPO Price bandRs. 1026 to Rs. 1080 per share
Mankind Pharma IPO market lot13 equity shares and multiples
Mankind Pharma IPO minimum order quantity13 equity shares
Pre IPO equity share of promoters of Mankind Pharma79 %
Post IPO paid-up equity share of promoters of Mankind Pharma__ %
QIB portion reservation in Mankind Pharma IPO50 %
NIB portion reservation in Mankind Pharma IPO15 %
Retail portion reservation in Mankind Pharma IPO35 %
Retail individual bidder can apply in Mankind Pharma IPOup to 2 lakh (200,000) – Maximum 13 Lot
Retail individual discount in Mankind Pharma IPONA
Employees can apply in Mankind Pharma IPOup to 5 lakh (500,000)
Employees Reservation in Mankind Pharma IPONA
Employees Discount in Mankind Pharma IPONA
Listing of Mankind Pharma at ExchangesNSE, BSE
Fund raised from Anchor Investors in Pre-IPO of Mankind PharmaNA
Registrar of Mankind Pharma IPO issueKfin Technologies Private Limited
Mankind Pharma IPO highlights

Mankind Pharma IPO important dates regarding bidding, allotment, listing, refund etc. :

The probable dates regarding bidding, allotment, listing, refund of Mankind Pharma IPO are mentioned below.

Mankind Pharma IPO opens on25.04.2023
Mankind Pharma IPO Closes on27.04.2023
Allotment basis date of Mankind Pharma IPO03.05.2023
Money refund date of Mankind Pharma IPO04.05.2023
Shares of Mankind Pharma in Demat Account05.05.2023
Mankind Pharma IPO listing date on NSE, BSE08.05.2023
Mankind Pharma IPO important dates regarding bidding, allotment, listing, refund etc.

How much shares of Mankind Pharma IPO are being offered?

Type of Issue (Fresh / OFS)No. of Equity shares offeredAmount of Equity shares
Total Issue size₹ 4326.36 Cr
Fresh Issue size₹ 0 Crore
Offer for Sale (OFS)₹ 4326.36 Cr
Employee Reservation
No. of Equity shares offered of Mankind Pharma IPO

IPO Red Herring Prospectus (RHP) of Mankind Pharma:

Click here for IPO RHP of Mankind Pharma on SEBI website.

Business of Mankind Pharma: (Source – RHP)

We are India’s fourth largest pharmaceutical company in terms of Domestic Sales and third largest in terms of sales volume for MAT December 2022 (Source: IQVIA Dataset, IQVIA TSA MAT December 2022 Dataset for India (For FY20-22)). We are engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. We are focused on the domestic market, as a result of which our revenue from operations in India contributed to 97.60% of our total revenue from operations for the Financial Year 2022, which was one of the highest among peers identified by IQVIA (being key pharmaceutical companies operating in similar therapeutic areas, as highlighted in “Industry Overview” on page 158) (“Peers Identified by IQVIA”) (Source: IQVIA Report). We have primarily grown organically and are the youngest company among the five largest pharmaceutical companies in India, in terms of Domestic Sales in 2022 (Source: IQVIA Dataset, Annual filings / company data). We operate at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices, and have an established track record of building and scaling brands in-house. We have created 36 brands in our pharmaceutical business that have each achieved over ₹500.00 million in Domestic Sales for MAT December 2022 (Source: IQVIA Dataset, IQVIA TSA MAT December 2022 Dataset for India (For FY20-MAT Dec 22)). We have one of the largest distribution networks of medical representatives in the Indian pharmaceutical market (“IPM”) and over 80% of doctors in India prescribed our formulations for MAT December 2022 (Source: IQVIA Dataset, annual filings by respective companies with stock exchanges, IQVIA Medical Audit MAT Dec 2022 for MAT Mar’20-22 and MAT Dec’22), which has assisted us in establishing our brands in India. Our brands have enabled us to consistently generate the highest share of drug prescriptions in the IPM over the Financial Years 2018 to 2022 (Source: IQVIA Dataset, IQVIA 191 Medical Audit MAT Dec 2020 for MAT Mar’18-19, IQVIA Medical Audit MAT Dec 2022 for MAT Mar’20-22 and MAT Dec’22). Further, in our Covered Markets, we were ranked second by market share for MAT December 2022 (Source: IQVIA Dataset, IQVIA TSA MAT December 2022 Dataset for India (For FY20-22)).

Check IPO Dashboard for other IPOs :

Disclaimer: Kindly verify from RHP and concerned company for any clarification.

Leave a Reply

%d bloggers like this: